Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T60538 |
SARS-CoV-2-IN-14
3',5-Dichlorosalicylanilide |
SARS-CoV | Microbiology/Virology |
SARS-CoV-2-IN-14 是一种有效的、可口服的 SARS-CoV-2 抑制剂(IC50 :0.39 μM),是一种氯硝柳胺类似物。SARS-CoV-2-IN-14在人血浆和肝 S9 酶测定中比氯硝柳胺稳定性更强。SARS-CoV-2-IN-14以口服的方式给药可以提高其生物利用度和半衰期。 | |||
T79462 |
SARS-CoV-2 3CLpro-IN-14
|
SARS-CoV | Microbiology/Virology |
SARS-CoV-2 3CLpro-IN-14(compound 11j)为口服活性SARS-CoV-2 3CLpro抑制剂,于Vero E6细胞中对SARS-CoV-2展现出高效抗活性(EC50=0.18 μM),且具备低细胞毒性(CC50>50 μM)。 | |||
T4988 |
Boceprevir
SCH 503034,EBP 520,波普瑞韦 |
HCV Protease; SARS-CoV | Microbiology/Virology; Proteases/Proteasome |
Boceprevir (SCH 503034) 是一种口服有效的选择性 HCV NS3 蛋白酶抑制剂。在酶试验中的 Ki 为 14 nM,在基于细胞的复制子试验中 EC90 为 350 nM。它也是 SARS-CoV-2 3CLpro 抑制剂。 | |||
T78725 | SARS-CoV-2 nsp14-IN-3 | SARS-CoV | Microbiology/Virology |
SARS-CoV-2 nsp14-IN-3 (4975)为一种针对SARS-CoV-2 Nsp14 N7-甲基转移酶的抑制剂,具有IC50值为7 μM。 | |||
T69536 |
MMT5-14
|
||
MMT5-14 is a SARS-CoV-2 inhibitor. MMT5-14 showed 2- to 7-fold higher antiviral activity in four variants of SARS-CoV-2. By reducing premature hydrolysis in hamsters, MMT5-14 increased the prodrug concentration by 200- to 300-fold in the plasma and lungs but also enhanced lung accumulation of the active metabolite triphosphate nucleosides (NTP) by 5-fold. |